Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group

Nicole T. Baumer1, Mara L. Becker2, George T. Capone3, Kathleen Egan4, Juan Fortea5,6,7, Benjamin L. Handen8, Elizabeth Head9, James E. Hendrix10, Ruth Y. Litovsky11,12, Andre Strydom13,14, Ignacio E. Tapia15 and Michael S. Rafii16*

Abstract

The recent National Institute of Health (NIH) INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) initiative has bolstered capacity for the current increase in clinical trials involving individuals with Down syndrome (DS). This new NIH funding mechanism offers new opportunities to expand and develop novel approaches in engaging and effectively enrolling a broader representation of clinical trials participants addressing current medical issues faced by individuals with DS. To address this opportunity, the NIH assembled leading clinicians, scientists, and representatives of advocacy groups to review existing methods and to identify those areas where new approaches are needed to engage and prepare DS populations for participation in clinical trial research. This paper summarizes the results of the Clinical Trial Readiness Working Group that was part of the INCLUDE Project Workshop: Planning a Virtual Down Syndrome Cohort Across the Lifespan Workshop held virtually September 23 and 24, 2019.

Keywords: Down syndrome, Intellectual disability, Clinical trials, Clinical research, Research engagement, Recruitment

Background/introduction

The INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) project was launched in June 2018 in support of a Congressional directive in the fiscal year (FY) 2018 Omnibus Appropriations. The directive called for a new trans-NIH research initiative on critical health and quality-of-life needs for individuals with Down syndrome (DS) and resulted from advocacy from the community, NIH commitment, and generous support from Congress. This program is developing a portfolio of scientific opportunities that span the spectrum from basic science to clinical research. Important insights are being gained from INCLUDE studies, and the capacity building (especially training for a cadre of investigators who will advance the field) that the program has accelerated provides confidence that this research trajectory will enhance the lives of people with DS.

The NIH INCLUDE project hosted a workshop titled “Planning a Virtual Down Syndrome Cohort Across the Lifespan Workshop.” Groups interacted via teleconferences and email during a 3-month preparation period. A 2-day face-to-face meeting was held virtually, September
and their families experience ethical and logistical barriers. These include barriers that individuals with DS and more broadly within neurodevelopmental disabilities (NDDs) have impacted the success of clinical trials in DS, development of new tools to detect AD-related cognitive decline in adulthood [3, 4]. Working groups have also evaluated potential outcome measures that can be used in clinical trials in the areas of cognition and behavior [5]. However, despite these advances, clinical trial research, particularly that focused on cognition, has been slow to progress and poses unique challenges [6, 7]. Several issues have impacted the success of clinical trials in DS, and more broadly within neurodevelopmental disabilities (NDDs). These include barriers that individuals with DS and their families experience, ethical and logistical barriers that researchers face, and challenges with clinical trial research design and interpretation.

**Current state of clinical trials in the Down syndrome population**

Ongoing clinical trials with individuals with DS address a wide range of conditions and issues, such as Alzheimer’s disease (AD) dementia, cardiac disease, metabolic disorders and obesity, autoimmune disorders, obstructive sleep apnea (OSA), leukemia, behavioral, and mental health issues. Advances in medical care have improved overall health and extended the life span of individuals with DS. Current research is focused on development, cognition, with the goal of maximizing functional outcomes and improving their quality of life.

Great strides have been made in observational and behavioral research in DS, with thorough characterization of development and cognition [1, 2], as well as development of new tools to detect AD-related cognitive decline in adulthood [3, 4]. Working groups have also evaluated potential outcome measures that can be used in clinical trials in the areas of cognition and behavior [5]. However, despite these advances, clinical trial research, particularly that focused on cognition, has been slow to progress and poses unique challenges [6, 7]. Several issues have impacted the success of clinical trials in DS, and more broadly within neurodevelopmental disabilities (NDDs). These include barriers that individuals with DS and their families experience, ethical and logistical barriers that researchers face, and challenges with clinical trial research design and interpretation.

**Ethical and logistical barriers faced by researchers**

Challenges with recruitment, retention, consenting/assenting, and logistics, safety, and efficacy have also long impacted clinical trial research in DS and special considerations are needed for success [6, 7]. Given the historical context of exploitation, there are issues surrounding the ethical and legal implications for conducting research with individuals with intellectual disability (ID) [11, 12]. For example, some researchers may be reluctant to include people with ID in their research for several reasons: they may inappropriately presume inability; they may be concerned about the capacity of the individual to understand risks and benefits and provide consent or assent to participate; or they may consider those with ID to be vulnerable and in need of protection from potential harms of research. While DS researchers may be well trained and experienced, and have comfort in addressing these issues, researchers less familiar with DS or ID, but who study health issues relevant to DS may not be. Choice of participants can also be problematic, as those
with more severe impairments who may not be able to comply with study demands may not be well represented by findings originating from study participants with milder impairments who are better able to participate in research.

**Challenges specific to clinical trials targeting cognition**

There are specific challenges to clinical trials that target cognition, neurodevelopment, and neurodegeneration. These include heterogeneity within the population, interindividual variability, lack of standard endpoints to assess efficacy, placebo effects, reliance on informant-based questionnaires that require the same informant at multiple time points, and complexity in interpretation of findings. Current research most commonly involves those who have mild-moderate ID, and findings may not be generalizable to those with more severe impairment.

Clinical trials in DS have faced similar challenges to clinical trials in other NDDs. For example, in Fragile X, despite great success in understanding genetic and mechanistic causes of cognitive impairments and positive findings in mouse models, human studies of targeted pharmacologic treatments for cognition have not yet shown significant improvement in outcomes, and some pharmaceutical companies have discontinued further drug development [13]. However, there are many complexities to interpreting the available findings. It may be that studies are too quick to conclude that negative findings in a trial prove that a treatment is ineffective under all conditions or that the presumed underlying pathophysiological mechanisms are not valid [14]. For example, some treatments may be effective in certain subgroups of the population, at a different time in development, or under different conditions.

Without potential biomarkers of treatment response, human trials need to rely on behavioral outcomes, which reflect combined effects of many different factors such as learning and environment. Additionally, the behavioral outcome measures may not be sensitive enough to treatment effects, or best suited to the population studied or what is most relevant to families and people with DS. Standardized behavioral-based assessments have floor and ceiling effects and direct measurement testing batteries may over- or underestimate participant's skills because they are not geared to their specific profile. Reliance on informant-based questionnaires is also particularly susceptible to strong placebo effects in NDDs [15].

Variability in cognition, behavior, language, and adaptive skills is seen in people with DS, and skills in these domains evolve across the lifespan, with environmental influences playing a role in ways that are not well characterized or understood. Furthermore, how medical and mental health conditions that occur at different times over the lifespan further influence neurodevelopment and outcomes.

While a longitudinal lifespan approach would help to answer important clinical questions that address both neurodevelopmental and neurodegenerative aspects of DS, there are many challenges to a lifetime approach as brain development, organization, maturation, and functioning evolve over time, and there may be critical windows for potential treatments to have desired effects. Additionally, pharmacological treatments targeting cognition or learning may need to be paired with structured therapy/teaching paradigms and study impact over longer time periods to adequately assess effectiveness of a drug that has the potential to enhance the learning process.

**Clinical trials readiness working group objectives**

The Clinical Trial Readiness Working Group was provided with key questions and tasked with developing responses that could serve as a roadmap for efforts going forward in advancing clinical research efforts in DS and increasing participation among persons with DS in future clinical trials. The questions focused on (1) identification of approaches to facilitate recruitment and retention of research participants, including underrepresented groups, (2) cohort preparation for clinical trials with special considerations for clinical trials across the lifespan, and (3) building a pipeline of investigators with DS clinical trial experience. In exploring these questions, several themes emerged and fostered development of the recommendations that follow.

**Key questions:**

1. Recruitment and retention: what approaches can facilitate recruitment and retention of families or participants to build a DS cohort and understand natural history, including underrepresented groups?
2. Cohort development across the lifespan: how can we ensure that cohorts are prepared for those with DS across the lifespan for future clinical trials?
3. Building an investigator pipeline: how can we build the pipeline of investigators who have DS clinical trial experience?

**Recruitment and retention: strategies to promote engagement and inclusion**

*Engagement with individuals with DS, their families/care partners, and community advocacy organizations*

Ensuring that research teams include members from the groups studied has been increasingly recognized as an important aspect of research involving individuals with disabilities [7, 15]. The shift from “researching on” to “researching with” has helped investigators understand the types of outcomes that are perceived to be useful within the community and can contribute valuable information to study design and implementation [16].
The Working Group identified areas of need and suggestions for recruitment and retention of research participants, with particular focus on engaging and involving groups often underrepresented in medical research. Involving individuals with DS and their families at all phases of research and fostering and maintaining research collaborations are necessary to promote engagement and advance clinical research while helping to further the understanding of needs and priorities.

Surveys, focus groups, and consultation and advisory feedback from families and participants can be particularly helpful when developing study questions and designing clinical trials. This can help to ensure understandability and feasibility of study assessments, outcome measures, information and consent materials, and will help researchers understand the relevance of the study question to participants and how they would like information conveyed. Some family members may have professional expertise that aligns with clinical and scientific goals. Investigators should take a community-engaged/community-based participatory research approach (CBPR), in which they collaborate with the community, and incorporate stakeholders’ expertise, values, and priorities in all steps of the research process [17].

Community engagement and outreach events may enhance outreach and education and can be conducted in person or virtually. Social media, websites, and newsletters from advocacy organizations can be used to advertise studies. Partnering with DS associations and societies (e.g., National Down Syndrome Society (NDSS), Global Down Syndrome Foundation (GDSF), LuMind Foundation, National Down Syndrome Congress (NDSC), Trisomy 21 Research Society (T21RS)), and religious and community groups, government, and advocacy groups will also support this effort. Importantly, an individual and family’s experience in a trial not only impacts retention for that trial but impacts recruitment for future trials. Partnerships can be further strengthened and promoted by engagement in which materials and information about ongoing studies can be disseminated. These efforts can help to promote partnerships, buy-in, and willingness for individuals to be contacted in the future for research opportunities.

**Collaboration between researchers, clinicians, stakeholder groups, and advocacy organizations**

In addition to strong community engagement, successful recruitment will rely on collaboration among clinicians and researchers, stakeholder groups, and advocacy organizations. Strong relationships with referring clinical programs, and in collaboration with clinicians who have pre-existing relationships with potential participants, will enable research to be considered as an extension of clinical care, with both clinical and research existing synergistically. It is necessary to continue to build a strong network of clinical care centers for people with DS, and for researchers to collaborate closely with clinicians and to collaborate in study recruitment and study conduct, such as for collecting data from the clinical sample. Researchers should engage clinicians as partners and respect their involvement (e.g., the face of the study, collaborators on publications).

Partnerships between academic researchers and industry are needed to conduct large scale randomized, placebo-controlled clinical trials. Collaborations with researchers who focus on other areas of developmental disabilities may be useful to broaden the scope of endpoints. Continued collaborations with NIH and the Down Syndrome Medical Interest Group (DSMIG-USA), collaborations with researchers and clinicians, basic scientists, and clinical researchers are needed to further this effort.

**Engagement of underrepresented groups**

Engagement and involvement of minority groups who are underrepresented in biomedical research is a particular challenge. It is necessary to incorporate strategies that address cultural and language barriers, such as adapting information, providing translations for written documents and interpreters for oral communications, and targeting recruitment. It will be necessary to identify strategies to gain information about the ages, ethnicities, and races of people with DS in research catchment areas and clinical research sites and to work closely with the community to engage participants. Recruiting people from various backgrounds and minority groups can also be enhanced by inclusion of people on the research team that captures this diversity.

**Providing accessible information**

A careful and thorough process of communication is needed when conducting research in individuals with DS. Use of accessible information and repeated opportunities to communicate information and check for understanding are needed. Novel ways to address informed consent, such as through picture-based consents and electronic consenting platforms (eConsenting), are needed. For example, the U.S. Food and Drug Administration has guidance on use of electronic consents [18]. Involvement of individuals with DS and their families in reviewing consent materials is especially important. Individuals with DS may be inclined to give socially desired answers, so checking for understanding and use of visually accessible information is needed.

Timely and accurate dissemination of important findings, including safety information and results, is
imperative. New and creative ways to acknowledge participation in research and to share and distribute study results are crucial. Information should be shared in formats that are appropriate to the audience, such as through a newsletter or infographic, rather than a journal article. For example, T21 RS COVID-19 infographic summaries, vetted through stakeholders and advocacy groups, have proved to be a successful method for dissemination of key research findings [19]. Providing a platform for patients and research participants to share their experience in research with others may also be a valuable tool for all stakeholders.

Reducing study burden
Trial burden may be decreased by using telemedicine and home visits, or by coordinating research with clinic visits or on nights or weekends, so as not to interfere with school, work and other activities and appointments. Budgets should reflect the additional cost required to bring in research staff on off-hours. It is also important to ensure that families, participants and care partners are appropriately supported to attend visits (e.g., travel arrangements and reimbursement, compensation for use of care hours, flexibility in timing of visits, adequate breaks during study visits.) Travel for adult participants, especially, can be a barrier to participation, and travel expenses should be included in the budget. Group travel for individuals with Down syndrome living together in a group home can save money and be enriching for participants. In addition, remote visits, such as via telemedicine, could also reduce travel burden for participants and expand research catchment areas. Direct to patient trials in which study treatments and procedures are delivered in the participant’s home could also be considered to optimize recruitment and minimize burden to patients and families [19].

Data collection in research areas of high interest (e.g., sleep, behavior, cognition, mental health) are extremely labor- and time-intensive to conduct. Development of select web-based, interactive assessment tools (point-click-scroll) will be helpful to partially replace the need for in-person visits. Some studies are also completed entirely online, such as the Alzheimer’s Prevention Trials web-based research study [20]. Efforts are needed to begin to validate these tools and compare to gold-standard assessments, and also to collect data longitudinally to determine test-retest reliability. Feasibility trials/pilot studies are likely to be needed before larger scale trials are conducted.

Legal and ethical considerations
Autonomy and self-determination must be respected and balanced with the responsibility to protect vulnerable individuals from potential risks of participation in research studies, thus the informed consent process, in particular, demands careful planning.

Given the ID associated with DS, as well as potential emotional/behavioral conditions that influence decisions, individuals with DS must be supported in research decision-making. In many cases, and depending on the legal framework, a surrogate or proxy decision maker is involved, and a legally authorized representative makes decisions about participation. Many individuals are comfortable receiving assistance from trusted family and friends to help them with decisions. Even for individuals who cannot provide legal consent, they may be able to express their thoughts and feelings about participating and exercise some choice. Assent—or willingness of the prospective participant to go along with or not object to the study—is essential, even when there is a surrogate decision-maker.

Special consideration is also needed for recruitment/consenting of aging adults with DS or adults living in group homes who may lack a legally authorized representative or family informant. The legally authorized representatives of adults with DS often change over time, for example, from an aging parent to a sibling or professional caregiver. Each state or country has different regulations around consent for individuals with disabilities. This must be determined in advance to inform clinical trial development, with particular consideration of multisite/multiregional studies, and local/state regulations must be taken into consideration.

Cohort development across the lifespan
Cohort development across the lifespan is critical for readiness for future clinical trials. These trial ready cohorts might accelerate research for several clinical needs (e.g., AD and OSA), thus reducing the costs of performing different clinical interventions. Further development of reliable and valid clinical outcome measures across the lifespan and across a wide range of developmental abilities are needed. Longitudinal studies are needed to better understand the natural history of DS and its associated conditions, to identify DS-related norms, to help identify subgroups with characteristics, to understand what childhood factors may predispose to risk or resilience, and who may be good candidates for preventative interventions.

Many medical issues for adults with DS such as obesity and sleep apnea begin in childhood and childhood antecedents may play an important role in how these, and other adult-onset conditions, evolve. For example, AD, which is one of the most prevalent and challenging conditions for adults with DS, has genetic but also likely environmental origins early in childhood [21]. Some research in the general population has shown
associations between AD and increased exposure to adverse childhood experiences (including living in custody and difficult experiences with teachers) [22, 23]. In addition to research trials in older adults, longitudinal studies in DS will be needed in DS to understand early risk factors and the potential impact of childhood experiences. Additionally, the association between OSA in adults with AD is currently under investigation in the general population [24]. With high rates of OSA in people of all ages with DS, it will be important to understand whether OSA in childhood might impact later risk of AD. Similarly, research in typically developing children has shown that persistent sleep problems through childhood are associated with worse behavioral outcomes and quality of life. A longitudinal study in individuals with DS might be able to provide important insight into the association between sleep and health outcomes across the lifespan [25]. Furthermore, there are conditions that arise specifically in childhood, for example DS-associated arthritis that can affect long-term physical outcomes. DS-associated arthritis is under-recognized, has a more severe phenotype, and is difficult to treat. It can result in disruptions in motor development, unpredictable medication toxicity and significant long-term physical disability [26].

Ongoing work to accelerate the development, evaluation, and validation of new trial-enabling standardized outcome measures for use over the lifespan is also needed. Many measures currently used in neurotypical children and adults cannot be used in those with DS. Cognitive measures are needed that are normed for individuals with DS and age appropriate, which are sensitive to bidirectional change (i.e., can detect developmental growth and skill acquisition as well as decline), and that can be used in individuals with a wide range of abilities, including those with more severe ID [5].

While longitudinal lifespan studies are logistically challenging, through close collaboration among the DS community and advocacy organizations, specialized pediatric and adult clinical DS programs, and researchers, large registries and clinical databases of well-characterized cohorts can be created and shared. NIH-funded Data Coordinating Centers [27] can lead these efforts by serving as a platform for linking investigators for collaborative research. Additionally, with opportunities for clinical research throughout the lifespan, more touchpoints and ongoing engagement can be fostered for future recruitment into clinical trials. Exposure to research results and sharing the successes in a case study can help build trust. Also, most publications are usually scientific and do not reach the target population. The recommendation is to publish for the target population on their websites and share these in DS conferences to convey results and findings to the population.

The timing of interventions will be critical to consider. In younger children, developmental change will be expected in the absence of intervention, and in older individuals, there may be points at which aberrant neurodevelopment or the later neurodegenerative cascade, are too far underway such that neurobiological consequences are irreversible and functioning cannot be altered. Additionally, specific brain areas impacted in DS mature at different rates and manifestations of their disrupted development change across the lifespan, suggesting that some pharmacological targets may be most effective at different time points in development. For these reasons, targeting younger individuals for treatment and prevention trials, in addition to older adults, may be an additional important approach.

Clarity is needed on a regulatory pathway for new drugs for DS, as the typical progression of drug development that is initiated in neurotypical adults, then children, may be problematic. It is not clear that demonstration of safety in a neurotypical population would predict safety in DS. In addition, individuals with DS are at increased risk for numerous co-occurring conditions that require chronic medications and very little is understood about drug biotransformation in DS, despite observed differences in drug response and toxicity [28–30]. Dedicated pharmacodynamic and pharmacokinetic studies, such as those conducted through the Pediatrics Trials Network—currently investigating metabolism of Guanfacine in Down syndrome—are needed more broadly in DS to determine drug disposition and response relationships, and to establish safety and dosing recommendations across the lifespan. Additionally, training and expertise are needed for identifying and managing potential adverse events, particularly when participant reporting of side effects and problems may not be straightforward.

Coordinated efforts across many sites will be needed to build large cohorts, and leverage existing infrastructure, including Alzheimer’s Disease Research Centers (ADRCs), Centers for Excellence in Developmental Disabilities (CEDDs), Intellectual and Developmental Disability Research Centers (IDDRCs) and others. Harmonization of test batteries across studies and across age groups is desired so that results can be compared and aggregated across studies. Several strategies can help with cohort development, including continued support of DSConnect and similar efforts to build a registry of interested participants, continued work to prepare and maintain lists and coordination of existing cohorts through the Data Coordinating Centers, and ensuring that new research study design is tailored and compatible with existing cohorts. This involves ongoing work
Building an investigator pipeline in Down syndrome research

Coincident with bolstering clinical trial participation by members of the DS community, there is a critical need to have clinical research sites trained and resourced to conduct such studies. The Working Group offered several recommendations to support this effort. The INCLUDE infrastructure can be used to bring in early stage as well as established investigators into the DS research space by capitalizing on existing training mechanisms, such as NIH Career Development and Training pathways (e.g., K23, T32 training awards).

Interest in DS research can be expanded and fostered by engaging clinicians, researchers, and trainees including those who are not focused solely or primarily on DS or even ID and providing training and mentorship. To encourage DS clinicians to participate, it will be necessary to offer training bootcamps to provide skills in clinical trial design, implementation, and funding, as well as ongoing mentoring opportunities.

In order to encourage other researchers to include people with DS or other intellectual and developmental disabilities in their research, it will be necessary to provide training on how to interact with and include people with DS.

Training opportunities can be built into NIH clinical trials infrastructure such as the Pediatric Trials Network (PTN) and Alzheimer’s Clinical Trials Consortium (ACTC). For example, ACTC launched the IMPACT AD training course in 2020. Lectures are given by national leaders in Alzheimer’s Disease and Related Dementias (ADRD) trials, and attendees have the opportunity to work closely with the field’s top investigators in small group workshops. Groups such as the ADRC can be encouraged to recruit and help train investigators interested in focusing on DS. There is now a DS module developed by the National Alzheimer’s Coordinating Center (NACC) that can be implemented at all ADRCs. It will be important to develop international links and collaborative networks via organizations such as the Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) and T21RS to capitalize on global expertise. All NIH funded ADRCs also now include a Research Education Component that could be coordinated to provide training modules on the importance of research in people with DS and Alzheimer disease.

The PTN also launched a PTN Down Syndrome 2020 Virtual meeting to introduce to the larger network and interested collaborators the therapeutic challenges faced by children with DS; opinions of community advocates, individuals, and parent/family on engaging in current and future research; lessons learned from current efforts to enroll patients with Down syndrome into an active PTN study; and input on a prospective randomize clinical trial protocol in development.

Existing IDDRCs can also be leveraged to fund post-docs and/or PhD positions in their labs to draw students from other fields into the DS space. This can be accomplished by offering CME activities and presenting workshops/symposia at national meetings focused on DS/ID [e.g., DSMIG-USA, DSMIG-UK, Child Neurology Society (CNS), American Academy of Neurology (AAN), AAIDD-Gatlinburg, and American Academy of Developmental Medicine and Dentistry (AADMD)] or with stakeholders not focused solely or primarily on DS or even IDD (e.g., AMA, APA, AAIC.) Finding ways to support student/young investigator attendance at these meetings will also be important.

Discussion/key points

Advancing research in DS will require ambitious and collaborative efforts that reach across the lifespan and include researchers, clinicians, individuals with DS and their families, advocacy groups, and industry. The Clinical Trial Readiness Working Group has identified many challenges and opportunities for these efforts and has suggested approaches in developing some of the infrastructure and methods needed to conduct clinical trials successfully in people with DS.

Specifically, the Working Group highlighted the importance of the following:

1- Stakeholder engagement from the inception of any research project.
2- Ethical, accessible (culturally and cognitively appropriate) recruitment materials, ensure collection of assent as part of the consenting process if a legal guardian is providing consent, study materials, and dissemination of results available in different languages.
3- A lifespan approach from time of diagnosis (including prenatal diagnosis) to death both to evaluate childhood antecedents of adult disease or decline and to evaluate effects of interventions.
4- Development of appropriate tools to assess outcomes in health, quality of life, cognitive functioning and behavioral/mental health that can be used across institutions and age ranges.
5- Workforce development of a pipeline of researchers and clinicians to collaborate in ongoing research efforts.

Conclusions
As we develop more advanced infrastructure to translate research towards clinical benefit for individuals with DS, it will be critical to continue the efforts described by the Working group to achieve the best possible outcomes and ensure that important research opportunities are accessibility for all.

Abbreviations
NIH INCLUDE: National Institute of Health INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromeE; DS: Down syndrome; NDD: Neurodevelopmental disabilities; ID: Intellectual disability; NDSS: National Down Syndrome Society; GDSF: Global Down Syndrome Foundation; NDSC: National Down Syndrome Congress; T21R3: Trisomy 21 Research Society; DSMIG-USA: Down Syndrome Medical Interest Group-USA; OSA: Obstructive Sleep Apnea; ADRD: Alzheimer's Disease Research Centers; CEDD: Centers for Excellence in Developmental Disabilities; IDRC: Intellectual and Developmental Disability Research Centers; PTN: Pediatric Trials Network; ACTC: Alzheimer's Clinical Trials Consortium; ADRED: Alzheimer's Disease and Related Dementias; IMPACT-AD: Institute on Methods and Protocols for Advancement of Clinical Trials in ADRED; NACC: National Alzheimer's Coordinating Center; ISTAART: International Society to Advance Alzheimer's Research and Treatment; CNS: Child Neurology Society; AAN: American Academy of Neurology; AADMD: American Association on Intellectual and Developmental Disabilities; AADMD: American Academy of Developmental Medicine and Dentistry; AMA: American Medical Association; APA: American Psychological Association; AAIC: Alzheimer's Association International Conference.

Acknowledgements
We would like to thank Dr. Kelly King and Dr. Melissa Parsi of NIH for their collaboration on this manuscript.

Authors’ contributions
All authors have reviewed this manuscript to report. NB and MSR participated in the working group that served as the basis for this manuscript and also led the writing of the manuscript. MLB, GTC, KE, BLH, EH, JEH, RYL, AS, and IET participated in the working group and provided comments and edits to the final manuscript. The authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
All authors have reviewed this manuscript.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Pediatrics, Duke University School of Medicine, Durham, USA. 2Department of Pediatrics, Kennedy Krieger Institute, The Johns Hopkins School of Medicine, Baltimore, USA. 3Parent/Advocate, Virginia, USA. 4Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain. 5CIBERNE, Madrid, Spain. 6Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, Spain. 7Department of Psychiatry, University of Pittsburgh, Pittsburgh, USA. 8Department of Pathology & Laboratory Medicine, University of California, Irvine, USA. 9LuMind IDSC Foundation, Burlington, USA. 10Waisman Center, University of Wisconsin, Madison, USA. 11Department of Communication Sciences and Disorders, University of Wisconsin, Madison, USA. 12Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, London, UK. 13King's College London & South London and the Maudsley NHS Trust, London, UK. 14Division of Pulmonary and Sleep Medicine, Children's Hospital of Philadelphia Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. 15Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, Los Angeles, USA.

Received: 22 October 2021 Accepted: 10 March 2022
Published online: 23 March 2022

References
1. Channell MM, Mattie LJ, Hamilton DR, Capone GT, Mahone EM, Sherman SL, et al. Capturing cognitive and behavioral variability among individuals with Down syndrome: a latent profile analysis. J Neuropedir Dement. 2021. https://doi.org/10.1186/s11689-021-09365-2.
2. Chapman RS, Hesketh LJ. Behavioral phenotype of individuals with Down syndrome. Ment Retard Dev Disabil Res Rev. 2000;6:84–95.
3. Startin CM, Lowe B, Hamburg S, Hithersay R, Strydom A. Validating the cognitive scale for Down syndrome (CS-DS) to detect longitudinal cognitive decline in adults with Down syndrome. Front Psychiatry. 2019. https://doi.org/10.3389/fpsyt.2019.00158.
4. Aschenbrenner AJ, Baksh RA, Benejam B, et al. Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease. Alzheimer's Dement. 2021. https://doi.org/10.1002/ dad2.12184.
5. Esbensen AJ, Hooper SR, Fidler D, et al. Outcome measures for clinical trials in Down syndrome: Am J Intellect Dev Disabil. 2017;122:247–81.
6. Heller JH, Spiridigliozzi GA, Crissman BG, Sullivan-Saarela JA, Li JS, Kishnani PS. Clinical trials in children with Down syndrome: issues from a cognitive research perspective. Am J Med Genet C: Semin Med Genet. 2006. https://doi.org/10.1002/ajmg.c.30103.
7. Lee SE, Duran-Martinez M, Khantsis S, Bianchi DW, Guedj F. Challenges and opportunities for translation of therapies to improve cognition in Down syndrome. Trends Mol Med. 2020. https://doi.org/10.1016/j.tolle.2019.10.001.
8. Kramer-Roy D. Using participatory and creative methods to facilitate emancipatory research with people facing multiple disadvantage: a role for health and care professionals. Disabil Soc. 2015. https://doi.org/10.1080/09687599.2015.1090955.
9. Christensen KM, Hojlo M, Milikken A, Baumer NT. Parent attitudes toward enhancing cognition and clinical research trials in Down syndrome: a mixed methods study. J Dev Behav Pediatr. 2021. https://doi.org/10.1097/ DBP0000000000000900.
10. Reines V, Charen K, Rosser T, Eisen A, Sherman SL, Visootsak J. Parental perspectives on pharmacological clinical trials: a qualitative study in Down syndrome and fragile X syndrome. J Genet Couns. 2017. https://doi.org/10.1007/s10897-017-0111-x.
11. Frankena TK, Naaldenberg J, Cardol M, Linehan C, van Schrojenstein Lantman-de Valk H. Active involvement of people with intellectual disabilities in health research - a structured literature review. Res Dev Disabil. 2015. https://doi.org/10.1016/j.ridd.2015.08.004.
12. Freedman R. Ethical challenges in the conduct of research involving persons with mental retardation. Ment Retard. 2001. https://doi.org/10.1353/mrj.2001.0190.
13. Jacquemont S, Berry-Kravis E, Hagemann R, van Raison F, Gasparini F, Apostol G, et al. The challenges of clinical trials in fragile X syndrome. Psychopharmacology. 2014. https://doi.org/10.1007/s00213-013-3289-0.
14. Jeste SS, Geschwind DH. Clinical trials for neurodevelopmental disorders: at a therapeutic frontier. Sci Transl Med. 2016. https://doi.org/10.1126/scitranslmed.a98774.

15. Siafis S, Çray Q, Schneider-Thoma J, et al. Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis. Mol Autism. 2020. https://doi.org/10.1186/s13229-020-00372-z.

16. Morih A. Using life history with students with disabilities: researching with, rather than researching on. Educ Rev. 2020. https://doi.org/10.1080/00331911.2018.1550054.

17. Christopher S, Watts V, McCormick AW-G, Young S. Building and maintaining trust in a community-based participatory research partnership. Am J Public Health. 2008. https://doi.org/10.2105/AJPH.2007.125757.

18. FDA Guidance on Electronic Consent. In: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-electronic-informed-consent-clinical-investigations-questions-and-answers. Accessed 22 Oct 2020.

19. Aisen PS, Sperling RA, Cummings J, Donohue MC, Langford O, Jimenez-Maggio RA, Rissman RA, Walter S, Clanton T, Raman R. The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) Project: An Overview. J Prev Alzheimers Dis. 2020;7(4):208–12. https://doi.org/10.14283/jpad.2020.45.

20. Alzheimer Prevention Trials Webstudy. In: https://www.aptrwebstudy.org/en/welcome. Accessed 22 Oct 2020.

21. Karmiloff-Smith A, Al-Janabi T, D’Souza H, et al. The importance of understanding individual differences in Down syndrome. F1000Research. 2016. https://doi.org/10.12688/f1000research.7506.1.

22. Donley GAR, Lönnroos E, Tuomainen T-P, Kauhanen J. Association of childhood stress with late-life dementia and Alzheimer’s disease: the KIHD study. Eur J Pub Health. 2018. https://doi.org/10.1093/eurpub/cdy134.

23. Tani Y, Fujiwara T, Kondo K. Association between adverse childhood experiences and dementia in older Japanese adults. JAMA Netw Open. 2020. https://doi.org/10.1001/jamanetworkopen.2019.20740.

24. Andrade AG, Bubu OM, Varga AW, Osorio RS. The relationship between obstructive sleep apnea and Alzheimer’s disease. J Alzheimer’s Dis. 2018. https://doi.org/10.3233/JAD-179998.

25. Williamson AA, Mindell JA. Cumulative socio-demographic risk factors and sleep outcomes in early childhood. Sleep. 2020. https://doi.org/10.1093/sleep/zsz233.

26. Niece A, Talib N, Lovell D, Smith C, Becker ML, Jones JT. Assessment and treatment of Down syndrome-associated arthritis: a survey of pediatric rheumatologists. Pediatr Rheumatol. 2020;18:57.

27. NIH INCLUDE Data Coordinating Center. In: https://includedcc.org. 2020. Accessed 22 Oct 2020.

28. Garré ML, Relling M, Kalwinsky D, Dodge R, Crom WR, Abromowitz M, et al. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr. 1987. https://doi.org/10.1016/S0022-3476(87)80131-2.

29. Uffmann M, Rasche M, Zimmermann M, et al. Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. Blood. 2017. https://doi.org/10.1182/blood-2017-01-765057.

30. Jones JT, Talib N, Lovell D, Becker ML. Clinical features and treatment of Down syndrome arthropathy: experience from two US tertiary hospitals. Pediatr Drugs. 2019. https://doi.org/10.1007/s40272-018-0322-0.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions